NO20042681L - Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav - Google Patents

Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav

Info

Publication number
NO20042681L
NO20042681L NO20042681A NO20042681A NO20042681L NO 20042681 L NO20042681 L NO 20042681L NO 20042681 A NO20042681 A NO 20042681A NO 20042681 A NO20042681 A NO 20042681A NO 20042681 L NO20042681 L NO 20042681L
Authority
NO
Norway
Prior art keywords
processes
preparation
venlafaxine hydrochloride
crystalline polymorph
new crystalline
Prior art date
Application number
NO20042681A
Other languages
English (en)
Norwegian (no)
Inventor
Jun Han
Yong Jai Lee
Kadum Abdul Nabi Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20042681L publication Critical patent/NO20042681L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20042681A 2001-12-05 2004-06-25 Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav NO20042681L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33582201P 2001-12-05 2001-12-05
PCT/US2002/038401 WO2003050075A1 (en) 2001-12-05 2002-12-03 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof

Publications (1)

Publication Number Publication Date
NO20042681L true NO20042681L (no) 2004-06-25

Family

ID=23313356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042681A NO20042681L (no) 2001-12-05 2004-06-25 Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav

Country Status (21)

Country Link
US (2) US7030164B2 (pl)
EP (1) EP1451145A1 (pl)
JP (1) JP2005511736A (pl)
KR (1) KR20050044673A (pl)
CN (1) CN1630631A (pl)
AR (1) AR037744A1 (pl)
AU (1) AU2002348266A1 (pl)
BR (1) BR0214742A (pl)
CA (1) CA2467593A1 (pl)
CO (1) CO5580818A2 (pl)
EC (1) ECSP045136A (pl)
HU (1) HUP0402524A2 (pl)
IL (1) IL162255A0 (pl)
MX (1) MXPA04005305A (pl)
NO (1) NO20042681L (pl)
NZ (1) NZ533363A (pl)
PL (1) PL370552A1 (pl)
RU (1) RU2004120285A (pl)
TW (1) TW200301101A (pl)
WO (1) WO2003050075A1 (pl)
ZA (1) ZA200405248B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
CA2574315A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
US20060020015A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
AU2005266997A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
JP2009502798A (ja) * 2005-07-21 2009-01-29 ワイス 神経系障害および状態の処置方法
KR20080056311A (ko) * 2005-10-19 2008-06-20 테바 파마슈티컬 인더스트리즈 리미티드 고순도1-[2-디메틸아미노-(4-메톡시페닐)에틸)시클로헥산올염산염의 제조 방법
NZ599480A (en) * 2007-02-21 2013-10-25 Sunovion Pharmaceuticals Inc Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
KR101477154B1 (ko) 2010-10-01 2014-12-29 산동 루예 파마슈티칼 컴파니 리미티드 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DE69429895T2 (de) 1993-06-28 2002-08-29 American Home Products Corp., Madison Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5530013A (en) 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
KR20030059206A (ko) 2000-10-19 2003-07-07 테바 파마슈티컬 인더스트리즈 리미티드 결정질 벤라팍신 염기 및 벤라팍신 히드로클로라이드의신규한 다형태, 이의 제조 방법
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
WO2002046140A1 (en) 2000-12-07 2002-06-13 Dr. Reddy's Laboratories Ltd. Novel crystalline polymorphic forms of venlafaxine hydrochloride and a process for their preparation
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)

Also Published As

Publication number Publication date
US20030109585A1 (en) 2003-06-12
ECSP045136A (es) 2004-07-23
KR20050044673A (ko) 2005-05-12
RU2004120285A (ru) 2005-04-10
US7030164B2 (en) 2006-04-18
TW200301101A (en) 2003-07-01
WO2003050075A1 (en) 2003-06-19
IL162255A0 (en) 2005-11-20
AU2002348266A1 (en) 2003-06-23
NZ533363A (en) 2005-10-28
CA2467593A1 (en) 2003-06-19
JP2005511736A (ja) 2005-04-28
PL370552A1 (pl) 2005-05-30
HUP0402524A2 (hu) 2005-03-29
US20060074131A1 (en) 2006-04-06
CN1630631A (zh) 2005-06-22
CO5580818A2 (es) 2005-11-30
MXPA04005305A (es) 2004-09-13
ZA200405248B (en) 2005-10-03
BR0214742A (pt) 2004-09-14
EP1451145A1 (en) 2004-09-01
AR037744A1 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
AP1830A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
NO329883B1 (no) Fremgangsmate for fremstilling av prostaglandiner og analoger derav og av mellomforbindelser, og forbindelser fremstilt derved
DK1446380T3 (da) Formoteroltartrafremgangsmåde og polymorf
NO20040794L (no) (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, forbindelser derav og anvendelser som en dopamin-gjenopptaks-inhibitor.
NO20042681L (no) Ny krystallinsk polymorf av venlafaxine-hydroklorid og fremgangsmater for fremstilling derav
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20071372L (no) Nye polymorfer av azabisykloheksan
NO20052676L (no) Polymorfer av bicifadin-saltsyre
NO20040292L (no) Fremgangsmate for fremstilling av 4-aminodifenylamin
NO20034236D0 (no) Ny fremgangsmåte for den industrielle syntese av tetraestere av 5-[bis(karboksymetyl)amino]-3-karboksymetyl-4-cyano-2-tiofenkarboksylsyre, oganvendelse isyntesen av bivalente salter av ranelinsyre og deres hydrater
UY27410A1 (es) Formas novedosas crudas cristalinas
NO20040388L (no) Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten
IL162171A0 (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
BRPI0411652A (pt) processo para a preparação de derivados de espirobenzoazepina substituìdos não-peptìdicos
MXPA04005307A (es) Clorhidrato de venlafaxina en forma de monohidrato y sus metodos de preparacion.
NO20064884L (no) Kjemisk fremgangsmate og ny krystallinsk form
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
NO20050885L (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
EA200300771A1 (ru) Новая соль бензоилгуанидина
EP1406614A4 (en) CARVEDILOLPOLYMORPH
DK1630169T3 (da) Mellemprodukter for LHRH-antagonist-synthesen, fremgangsmåde til deres fremstilling og fremgangsmåde til fremstilling af LHRH-antagonister
MXPA04003478A (es) Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application